Microchip Biotechnologies Licenses Technology for Developing Microfluidic Devices
News Aug 24, 2007
Microchip Biotechnologies, Inc. (MBI) and TEC Edmonton have entered into an exclusive patent license agreement that allows MBI to commercialize a University of Alberta invention that can improve the development of lab-on-a-chip devices and biosampling procedures.
“The licensing of this fundamental patent on manipulating beads on-chip continues to build upon our strong intellectual property position in microfluidic devices,” said Stevan Jovanovich, President and CEO of MBI.
“Microfluidic devices will play a critical role in next generation instrumentation in delivering fully automated, cost effective solutions life science, applied sciences, and diagnostic products for laboratory and field based applications,” he added.
California-based MBI will use the technology patented by TEC Edmonton officially called an Apparatus and Method for Trapping Bead Based Reagents within Microfluidic Analysis Systems (US Patent 6,432,290).
A team led by Dr. Jed Harrison, Professor and Chair in the Department of Chemistry, invented the technology to allow trapping of beads on-chip, as well as packing and unpacking the trapping zones, which significantly extends the applications of microfluidic analysis systems, such as those used in biodefense and genomics industries.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.